Your World of Legal Intelligence
 United Kingdom | +44 (0) 20 7284 8080

EMD Serono Acquires Neuroinflammatory Disease Specialist Chord Therapeutics.

Document Cited in Related
Vincent

MANews-(C)2009-2021

Germany-based science and technology company Merck KGaA's (OTC: MKKGY) US-based EMD Serono healthcare business sector, in the US and Canada, has focused expansion of its neurology pipeline with the acquisition of the rights to develop cladribine for the treatment of generalized myasthenia gravis and neuromyelitis optica spectrum disorder (NMOSD), the company said.

The company entered into an agreement to secure the global rights by acquiring Swiss-based biotech company Chord Therapeutics, focused on rare neuroinflammatory diseases.

Cladribine is a well characterized molecule that has been extensively studied across MS and oncologic disorders and has shown promising results in exploratory studies in gMG and NMOSD.

EMD Serono plans to leverage its existing capabilities to further develop an oral cladribine product tailored specifically for these indications.

The transaction is expected to be closed in early 2022 after satisfactory completion of customary closing conditions.

Generalized myasthenia gravis is a disease in which patients experience weakness in ocular, limb, and respiratory muscles and that has a significant impact on Quality of Life. It is estimated that 700,000 people around the world are living with gMG.

NMOSD, also known as DevicÂ's...

To continue reading

Request your trial
COPYRIGHT Normans Media Ltd.

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT